AbbVie
ABBV
3,053 hedge funds and large institutions have $195B invested in AbbVie in 2022 Q1 according to their latest regulatory filings, with 235 funds opening new positions, 1,155 increasing their positions, 1,331 reducing their positions, and 124 closing their positions.
90% more first-time investments, than exits
New positions opened: 235 | Existing positions closed: 124
39% more funds holding in top 10
Funds holding in top 10: 214 → 297 (+83)
21% more capital invested
Capital invested by funds: $161B → $195B (+$34.3B)
2% more funds holding
Funds holding: 2,982 → 3,053 (+71)
8% more call options, than puts
Call options by funds: $3.37B | Put options by funds: $3.13B
0.97% more ownership
Funds ownership: 67.42% → 68.39% (+0.97%)
13% less repeat investments, than reductions
Existing positions increased: 1,155 | Existing positions reduced: 1,331
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$2.74B |
| 2 |
JP Morgan Chase
New York
|
+$1.6B |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$611M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$602M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$547M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$821M |
| 2 |
Berkshire Hathaway
Omaha,
Nebraska
|
-$411M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$309M |
| 4 |
Bank of New York Mellon
New York
|
-$229M |
| 5 |
Barclays
London,
United Kingdom
|
-$211M |
ABBV Hedge Fund Activity: Q1 2022 in Review
3,053 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q1 2022, worth a combined $195B — up 21% from $161B a quarter earlier.
Buyers outnumbered sellers: 235 funds opened new ABBV positions and 124 closed out — a net gain of 111 holders — while 1,155 added to existing stakes and 1,331 trimmed.
The largest buyer was Capital International Investors, adding an estimated $2.74B. The largest seller was Franklin Resources, cutting an estimated $821M.
- 3,053 institutional investors held AbbVie (ABBV) as of Q1 2022, up from 2,982 in Q4 2021.
- Funds reported $195B of AbbVie stock for Q1 2022, up 21% quarter-over-quarter.
- 235 funds opened new AbbVie positions in Q1 2022 and 124 closed out, a net change of +111 holders.
- The largest AbbVie buyer in Q1 2022 was Capital International Investors, an estimated $2.74B added.
- The largest AbbVie seller in Q1 2022 was Franklin Resources, an estimated $821M sold.
Based on aggregated 13F filings for Q1 2022.